Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Montaser

Showing results (591-600 of 613) with videos related to

Pageof 62
Sort By:
Journal of Cardiovascular Electrophysiology|February 23, 2026
Pulsed Field Versus Radiofrequency Ablation in Concomitant Pulmonary Vein Isolation and LAA Occlusion: Impact on Peridevice Leak and Procedural EfficiencyMohammad Montaser Atasi, Shea Hubbard, Charles Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2022
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA TrialChung-Han Lee, Robert Motzer, Hamid Emamekhoo, et al.
Nature Genetics|November 17, 2023
Primate-specific ZNF808 is essential for pancreatic development in humansElisa De Franco, Nick D L Owens, Hossam Montaser, et al.
Molecular Cancer Therapeutics|October 17, 2014
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanomaDavid J Panka, Elizabeth Buchbinder, Anita Giobbie-Hurder, et al.
The Lancet. Oncology|September 14, 2016
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trialF Stephen Hodi, Jason Chesney, Anna C Pavlick, et al.
Cancer Discovery|March 12, 2021
Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory MelanomaCara Haymaker, Daniel H Johnson, Ravi Murthy, et al.
BMC Cancer|January 3, 2025
Real-world clinical outcome of unresectable locally advanced & de-novo metastatic pancreatic ductal adenocarcinoma: a multicentre retrospective studyMohamed Aseafan, Ali H Alfakeeh, Emad Tashkandi, et al.
Journal for Immunotherapy of Cancer|August 3, 2023
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysisElizabeth Lee Carpenter, Spencer Van Decar, Alexandra M Adams, et al.
Cancer Immunology, Immunotherapy : CII|August 31, 2022
Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trialAlexandra M Adams, Elizabeth L Carpenter, Guy T Clifton, et al.
Langenbeck'S Archives of Surgery|February 4, 2026
Endovenous chemical ablation and trendelenburg's (eCAT) operation for treating great saphenous vein varicosities: a single-arm open-label interventional studyWalied Khereba, Al Metwaly Ragab, Ayman Amen MohyElden, et al.
Pageof 62

Showing results (591-600 of 613) with videos related to

Sort By:
Pageof 62
Journal of Cardiovascular Electrophysiology|February 23, 2026
Pulsed Field Versus Radiofrequency Ablation in Concomitant Pulmonary Vein Isolation and LAA Occlusion: Impact on Peridevice Leak and Procedural EfficiencyMohammad Montaser Atasi, Shea Hubbard, Charles Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2022
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA TrialChung-Han Lee, Robert Motzer, Hamid Emamekhoo, et al.
Nature Genetics|November 17, 2023
Primate-specific ZNF808 is essential for pancreatic development in humansElisa De Franco, Nick D L Owens, Hossam Montaser, et al.
Molecular Cancer Therapeutics|October 17, 2014
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanomaDavid J Panka, Elizabeth Buchbinder, Anita Giobbie-Hurder, et al.
The Lancet. Oncology|September 14, 2016
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trialF Stephen Hodi, Jason Chesney, Anna C Pavlick, et al.
Cancer Discovery|March 12, 2021
Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory MelanomaCara Haymaker, Daniel H Johnson, Ravi Murthy, et al.
BMC Cancer|January 3, 2025
Real-world clinical outcome of unresectable locally advanced & de-novo metastatic pancreatic ductal adenocarcinoma: a multicentre retrospective studyMohamed Aseafan, Ali H Alfakeeh, Emad Tashkandi, et al.
Journal for Immunotherapy of Cancer|August 3, 2023
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysisElizabeth Lee Carpenter, Spencer Van Decar, Alexandra M Adams, et al.
Cancer Immunology, Immunotherapy : CII|August 31, 2022
Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trialAlexandra M Adams, Elizabeth L Carpenter, Guy T Clifton, et al.
Langenbeck'S Archives of Surgery|February 4, 2026
Endovenous chemical ablation and trendelenburg's (eCAT) operation for treating great saphenous vein varicosities: a single-arm open-label interventional studyWalied Khereba, Al Metwaly Ragab, Ayman Amen MohyElden, et al.
Pageof 62